Literature DB >> 17008878

Intermedin: a skin peptide that is downregulated in atopic dermatitis.

Friederike Kindt1, Silke Wiegand, Christoph Löser, Martin Nilles, Volker Niemeier, Sheau Yu Teddy Hsu, Martin Steinhoff, Wolfgang Kummer, Uwe Gieler, Rainer Viktor Haberberger.   

Abstract

Intermedin (IMD), also called adrenomedullin-2, is a peptide that belongs to the calcitonin/calcitonin gene-related peptide/amylin peptide family. IMD exerts many effects on the cardiovascular system, gastrointestinal tract, and central nervous system. Here, we analyzed the expression of the IMD peptide in human skin of healthy controls, in biopsies from lesional and non-lesional areas of atopic dermatitis (AD) skin, in cultured human keratinocytes, and in the HaCaT keratinocyte cell line at the transcriptional (quantitative reverse transcription-PCR) and translational (immunohistochemistry) level. IMD messenger RNA (mRNA) and protein could be detected in keratinocytes and human skin. Keratinocytes, nerve fibers, periglandular cells, arterial/arteriolar smooth muscle cells, and pericytes of dermal microvessels were intensely IMD-immunoreactive. The IMD mRNA was, compared to healthy skin, significantly reduced in lesional and non-lesional areas of AD skin. This was accompanied by a reduction of IMD immunoreactivity in pericytes of the upper dermis indicating that skin from AD patients is generally affected, and downregulation of IMD in AD skin is not a secondary phenomenon caused by acute inflammation but is a general characteristic of AD skin. These data further point to a role of IMD expressed by pericytes in conferring higher susceptibility of the skin of AD patients to inflammatory stimuli.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008878     DOI: 10.1038/sj.jid.5700576

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

Review 2.  The pharmacology of adrenomedullin 2/intermedin.

Authors:  Yanguo Hong; Debbie L Hay; Remi Quirion; David R Poyner
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Intermedin Restores Hyperhomocysteinemia-induced Macrophage Polarization and Improves Insulin Resistance in Mice.

Authors:  Yanli Pang; Yang Li; Ying Lv; Lulu Sun; Songyang Zhang; Yin Li; Yuhui Wang; George Liu; Ming-Jiang Xu; Xian Wang; Changtao Jiang
Journal:  J Biol Chem       Date:  2016-04-14       Impact factor: 5.157

4.  Intermedin is a new angiogenic growth factor.

Authors:  Robert S Smith; Lin Gao; Grant Bledsoe; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-10       Impact factor: 4.733

Review 5.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

6.  Calcitonin Peptide Family Members Are Differentially Regulated by LPS and Inhibit Functions of Rat Alveolar NR8383 Macrophages.

Authors:  Aichurek Soultanova; Zbigniew Mikulski; Uwe Pfeil; Veronika Grau; Wolfgang Kummer
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

7.  Intermedin 1-53 Inhibits Myocardial Fibrosis in Rats by Down-Regulating Transforming Growth Factor-β.

Authors:  Jian Fang; Jiangwei Luan; Gaohong Zhu; Chang Qi; Zhiyong Yang; Sheng Zhao; Bin Li; Xinzhong Zhang; Naipeng Guo; Xiaodong Li; Dandan Wang
Journal:  Med Sci Monit       Date:  2017-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.